10-Q: FibroBiologics Reports First Quarter 2024 Results, Cites Progress in Clinical Programs

FibroBiologics, a cell therapy company, reported a net loss of $8.46 million for the first quarter of 2024, alongside updates on its clinical programs and financial position.

Summary

• FibroBiologics, a cell therapy company, reported a net loss of $8.46 million for the quarter ended March 31, 2024, compared to a net loss of $2.415 million for the same period in 2023.
• The company's operating expenses totaled $3.45 million, with research and development expenses at $960,000 and general and administrative expenses at $2.49 million.
• The company completed a direct listing of its common stock on Nasdaq on January 31, 2024, which resulted in the conversion of preferred stock to common stock and cancellation of Series A preferred stock.
• As of March 31, 2024, FibroBiologics had cash and cash equivalents of $8.158 million and an accumulated deficit of $32.817 million.
• The company is developing several cell-based therapies, including CYWC628 for wound healing, CYMS101 for multiple sclerosis, and CybroCell for degenerative disc disease.
• FibroBiologics is planning to initiate a Phase 1/2 clinical trial in Australia for treatment of diabetic foot ulcers in 2025.
• The company is also conducting further research to determine the mode of action of fibroblasts in oligodendrocyte expansion and expects to file an IND application for a Phase 2 clinical trial in MS as funding allows.
• The company has a share purchase agreement in place that provides access to additional liquidity, and raised $2.819 million through this facility in February and March 2024.
• The company has a material weakness in internal controls over financial reporting due to a lack of segregation of duties.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While there is progress in clinical programs and a successful direct listing, the significant net loss, accumulated deficit, and going concern uncertainty weigh heavily on the sentiment. The company's reliance on future capital raises also adds to the negative sentiment.

Positives

• The company successfully completed a direct listing on Nasdaq, which provides access to public markets.
• The company has made progress in its preclinical studies for CYWC628, showing statistically significant acceleration in wound closure in diabetic mice.
• The company has received approval to conduct clinical investigations in Mexico using the fibroblast cell composition for patients with MS and has completed a Phase 1 study.
• The company has received IND clearance from the FDA, conditional upon approval of its master cell bank, to run a Phase 1 study for patients suffering from degenerative disc disease.
• The company has a share purchase agreement in place that provides access to additional liquidity.

Negatives

• The company reported a significant net loss of $8.46 million for the first quarter of 2024.
• The company has an accumulated deficit of $32.817 million.
• The company has a material weakness in internal controls over financial reporting due to a lack of segregation of duties.
• The company has incurred operating losses since inception and expects to continue to incur losses in the future.
• The company's ability to continue as a going concern is dependent on its ability to raise additional capital.
• The company currently does not generate revenues and may never achieve profitability.

Risks

• The company's ability to continue as a going concern is dependent on its ability to raise additional capital.
• The company has incurred operating losses since inception and expects to continue to incur losses in the future.
• The company's product candidates are in early stages of development and may not be successful.
• The company faces competition from other pharmaceutical companies with greater financial resources or expertise.
• The company's intellectual property may not be adequately protected.
• The company has a material weakness in internal controls over financial reporting.
• The company may not be able to obtain regulatory approvals for its product candidates.
• The company may not be able to commercialize its product candidates successfully.

Future Outlook

The company expects to continue to incur significant losses for the foreseeable future as it continues its research and development activities. The company plans to initiate a Phase 1/2 clinical trial in Australia for treatment of diabetic foot ulcers in 2025 and expects to file an IND application for a Phase 2 clinical trial in MS as funding allows. The company will need to raise additional capital to continue to fund its operations.

Management Comments

• Management has entered into a Share Purchase Agreement as of November 12, 2021, which provides the Company with access to additional liquidity.
• Management expects to continue to incur operating losses and negative cash flows.
• Management has evaluated the positive and negative evidence bearing upon the realizability of the Company's net deferred tax assets and has determined that it is more likely than not that the Company will not recognize the benefits of the net deferred tax assets.

Industry Context

The company operates in the competitive cell therapy industry, which is characterized by high research and development costs, regulatory hurdles, and the need for significant capital investment. The company's focus on fibroblast-based therapies is a novel approach, but it faces competition from established pharmaceutical companies and other biotech startups.

Comparison to Industry Standards

• FibroBiologics is an early-stage company, and its financial results are not directly comparable to established pharmaceutical companies with commercial products.
• The company's research and development expenses are typical for a biotech company in its stage of development.
• The company's net loss is significant, but it is not uncommon for early-stage biotech companies to operate at a loss while developing their product candidates.
• The company's cash position is relatively low, which highlights the need for additional capital raising.
• Compared to companies like Vericel (VCEL) or Organogenesis (ORGO) which have commercialized cell therapy products, FibroBiologics is still in the early stages of clinical development.
• The company's focus on fibroblast-based therapies is a unique approach compared to companies using other cell types like CAR-T cells or stem cells.

Related Party Transactions

• The company acquired certain in-process research and development and patent assets from FibroGenesis through Patent Assignment and Intellectual Property Cross-License Agreements.
• The company entered into an Agreement Regarding Right of First Negotiation (ROFN Agreement) with its Parent, FibroGenesis, which includes a payment of 15% of gross proceeds from equity investments prior to an IPO, Direct Listing or Sale of the Company.

Stakeholder Impact

• Shareholders face the risk of dilution from future capital raises and the potential for loss of investment if the company is unable to continue as a going concern.
• Employees may be impacted by potential cost-cutting measures if the company faces financial difficulties.
• Customers (potential patients) may benefit from the development of new cell-based therapies, but the timeline for commercialization is uncertain.
• Suppliers and creditors face the risk of non-payment if the company is unable to secure additional funding.

Next Steps

• The company plans to complete a technology transfer of its cell manufacturing processes to a contract development and manufacturing organization (CDMO).
• The company expects to produce a master cell bank, working cell bank, and drug product for use in clinical trials by year end 2024.
• The company is planning to initiate a Phase 1/2 clinical trial in Australia for treatment of diabetic foot ulcers in 2025.
• The company is conducting further research to determine the mode of action of fibroblasts in oligodendrocyte expansion and expects to file an IND application for a Phase 2 clinical trial in MS as funding allows.
• The company will continue to add staff, evaluate segregation of duties, and implement initiatives to improve its internal controls over financial reporting.

Key Dates

Keywords

cell therapy, fibroblasts, clinical trials, wound healing, multiple sclerosis, degenerative disc disease, biotechnology, research and development, Nasdaq, direct listing